Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk
Metrics: PDF 497 views | Full Text 1594 views | ?
Erika J. Lampert1, John L. Hays2, Elise C. Kohn1, Christina M. Annunziata1, Lori Minasian1, Minshu Yu1, Nicolas Gordon1, Tristan M. Sissung3, Victoria L. Chiou1, William D. Figg3, Nicole Houston1 and Jung-Min Lee1
1 Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
2 Ohio State University, Columbus, OH, USA
3 Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Keywords: high-grade serous ovarian cancer; BRCA wild type; olaparib; carboplatin
Received: February 26, 2019 Accepted: April 04, 2019 Published: April 23, 2019
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.